세계의 마이크로캐리어 시장 : 제품별, 용도별, 최종사용자별, 지역별 - 예측(-2029년)

The global microcarriers market is projected to reach USD 3.05 billion by 2029 from USD 2.08 billion in 2024, at a CAGR of 8.0% during the forecast period of 2024 to 2029. The factors contributing to the growth of the microcarriers market are rising investments in cell & gene therapy research, technological advancement in in microcarrier-based cell production and increasing applications of microcarrier in vaccines and therapeutics development. Furthermore, limitations in high-density cell culture and high cost of research and development are the factors expected to hinder the market growth over the forecast period.

"The pharmaceutical and biotechnology companies segment accounted for the largest share by end user in 2023."

Based on end user, the microcarriers market is segmented into pharmaceutical & biotechnology companies, academic and research institutes, contract research organizations & contract manufacturing organizations, and cell banks. The pharmaceutical & biotechnology companies segment accounted for the largest share of the microcarriers market in 2023. The larger share of this segment is mainly attributed to the growing regulatory approvals for cell-based vaccines, increased adoption of single-use bioprocessing products, recent developments in 3D cell culture, increased production of monoclonal antibodies (mAbs), and growing awareness of the advantages of cell-based vaccines.

"The US has continued to dominate the microcarriers market during the forecast period of 2024-2032."

The US leads the globe in biopharmaceutical research and investment, and it has the biggest biopharmaceutical market in the world. The need for safe and high-quality products in the healthcare industry, the growing number of patients with chronic diseases, the growing significance of biopharmaceuticals, and the rising investments and funding in biomedical research by government agencies and pharmaceutical and biotechnology companies are all driving factor for US market. Another important element fostering market expansion is the region's well-established presence of a number of industry participants. Among these important businesses are Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Corning Incorporated (US).

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 60% and Demand Side 40%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of key Companies Profiled in the Report:

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Sartorius AG (Germany), Corning Incorporated (US), FUJIFILM Holdings Corporation (Japan), BD (US), Eppendorf SE (Germany), Lonza (Switzerland), Getinge AB (Sweden), Bio-Rad Laboratories, Inc. (US), KURARAY CO., LTD. (Japan), Entegris (US), Teijin Limited (Japan), Asahi Kasei Corporation (Japan), Cellevate AB (Sweden), REPROCELL Inc. (Japan) denovoMATRIX GmbH (Germany), Bio-Link (China), bbi-biotech GmbH (Germany), G&G Technologies, Inc. (US), Solida Biotech GmbH (Germany), Smart MCs PTY LTD (Australia), BIONET (Spain), and PBS Biotech, Inc. (US).

Research Coverage:

This research report categorizes the gene therapy market by Product (Consumables (Media (Sera/Serum-based Media, Serum-free Media, and Other Media), Reagents, Microcarrier Beads (Natural (Cellulose, Collagen, Alginate, and Other Natural Material), Synthetic (Polystyrene, Dextran, PLGA, Polyvinyl Alcohol, and Other Synthetic Material), and Other Material), Cell Culture Vessels, Accessories, and Other Consumables, Equipment (Bioreactors (Stainless-Steel Bioreactors and Single-Use Bioreactors), Cell Counters, Filtration and Separation Systems, and Other Equipment)), by Application (Biopharmaceutical Production (Vaccine Production and Therapeutic Protein Production), Tissue Engineering and Regenerative Medicine (Cell and Gene Therapy, and Other Tissue Engineering and Regenerative Medicine Applications), and Other Applications), by End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations & Contract Manufacturing Organizations, Academic and Research Institutes, and Cell Banks) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the microcarriers market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations and acquisitions, and recent developments associated with the microcarriers market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall microcarriers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing adoption of microcarriers for cell-based vaccine production, Technological advancements to support microcarrier-based cell production, Rising investments in cell & gene therapy research, Growing preference for single-use technologies, and Increasing R&D spending for biopharmaceutical production), restraints (High cost of cell biology research and Limitations in high-density cell culture production), opportunities (Rising demand for 3D cell culture, Growing demand for mAbs and biosimilars, and High-growth potential of emerging economics), and Challenges (High costs associated with serum-free media and Microcarrier-cell detachment).
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals/launches in the microcarriers market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the microcarriers market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the microcarriers market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 REGIONS COVERED
  • 1.3.4 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
  • 2.2.2 PRIMARY DATA
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 KEY INSIGHTS FROM INDUSTRY EXPERTS
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 GROWTH RATE PROJECTIONS
• 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 MICROCARRIERS MARKET OVERVIEW
• 4.2 NORTH AMERICA: MICROCARRIERS MARKET, BY PRODUCT & COUNTRY, 2023
• 4.3 MICROCARRIERS MARKET, BY END USER, 2024 VS. 2029
• 4.4 MICROCARRIERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing demand for cell-based vaccines
    • 5.2.1.2 Rising technological advancements in microcarrier-based cell production tools
    • 5.2.1.3 Growing investments in cell & gene therapy research
    • 5.2.1.4 Rising preference for single-use technologies
    • 5.2.1.5 Increasing R&D spending for biopharmaceutical production
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of cell biology research
    • 5.2.2.2 Limitations in high-density cell culture production
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing demand for 3D cell culture
    • 5.2.3.2 Increasing demand for monoclonal antibodies and biosimilars
    • 5.2.3.3 Growth potential in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 High costs associated with serum-free media
    • 5.2.4.2 Complex microcarrier cell detachment process
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND, BY PRODUCT
  • 5.4.2 AVERAGE SELLING PRICE TREND OF KEY PLAYER, BY PRODUCT
  • 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT/FUNDING ACTIVITY
• 5.9 TECHNOLOGICAL ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Flow cytometry
    • 5.9.1.2 High-throughput screening technology
    • 5.9.1.3 Single-use technology
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Nanotechnology
    • 5.9.2.2 Artificial intelligence and machine learning
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Cell harvesting and separation
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA FOR HS CODE 841989
  • 5.11.2 EXPORT DATA FOR HS CODE 841989
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 REGULATORY LANDSCAPE
  • 5.13.1 REGULATORY ANALYSIS
  • 5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.14 PORTER'S FIVE FORCES ANALYSIS
  • 5.14.1 BARGAINING POWER OF SUPPLIERS
  • 5.14.2 BARGAINING POWER OF BUYERS
  • 5.14.3 THREAT OF NEW ENTRANTS
  • 5.14.4 THREAT OF SUBSTITUTES
  • 5.14.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 BUYING CRITERIA
• 5.16 IMPACT OF AI ON MICROCARRIERS MARKET
  • 5.16.1 INTRODUCTION
  • 5.16.2 MARKET POTENTIAL OF MICROCARRIERS
  • 5.16.3 AI USE CASE STUDY
  • 5.16.4 KEY COMPANIES IMPLEMENTING AI
  • 5.16.5 FUTURE OF AI IN MICROCARRIERS MARKET

6 MICROCARRIERS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 MEDIA
    • 6.2.1.1 Serum-based media
      • 6.2.1.1.1 Increasing biopharmaceutical production to drive segment
    • 6.2.1.2 Serum-free media
      • 6.2.1.2.1 Need for improved control and reproducibility to augment growth
    • 6.2.1.3 Other media
  • 6.2.2 REAGENTS
    • 6.2.2.1 Increasing focus on developing cell-based therapies to expedite growth
  • 6.2.3 MICROCARRIER BEADS
    • 6.2.3.1 Natural materials
      • 6.2.3.1.1 Cellulose
        • 6.2.3.1.1.1 Growing focus on sustainability in biopharmaceutical industry to boost market
      • 6.2.3.1.2 Collagen
        • 6.2.3.1.2.1 Shifting focus on personalized medicine to drive market
      • 6.2.3.1.3 Alginate
        • 6.2.3.1.3.1 Increasing demand for stem cell culture and regenerative medicine to aid growth
      • 6.2.3.1.4 Other natural materials
    • 6.2.3.2 Synthetic materials
      • 6.2.3.2.1 Polystyrene
        • 6.2.3.2.1.1 Increasing use of polystyrene for vaccine and monoclonal antibody production to support growth
      • 6.2.3.2.2 Dextran
        • 6.2.3.2.2.1 Growing utilization of dextran in cardiac regeneration, bone repair, and neurodegenerative diseases to fuel market
      • 6.2.3.2.3 PLGA
        • 6.2.3.2.3.1 Rising focus on 3D tissue engineering to encourage growth
      • 6.2.3.2.4 Polyvinyl alcohol
        • 6.2.3.2.4.1 Need for enhanced cell adhesion to advance growth
      • 6.2.3.2.5 Other synthetic materials
    • 6.2.3.3 Other materials
  • 6.2.4 CELL CULTURE VESSELS
    • 6.2.4.1 Increasing launches of 3D cell culture systems to augment growth
  • 6.2.5 ACCESSORIES
    • 6.2.5.1 Growing use of cell culture in industrial settings and bioreactors to drive market
  • 6.2.6 OTHER CONSUMABLES
• 6.3 EQUIPMENT
  • 6.3.1 BIOREACTORS
    • 6.3.1.1 Stainless steel bioreactors
      • 6.3.1.1.1 Rising focus on large-scale ease of production to boost market
    • 6.3.1.2 Single-use bioreactors
      • 6.3.1.2.1 Increasing use of single-use bioreactors by contract manufacturing organizations to stimulate growth
  • 6.3.2 FILTRATION & SEPARATION EQUIPMENT
    • 6.3.2.1 Growing adoption of advanced filtration & separation systems for bioprocess applications to drive market
  • 6.3.3 CELL COUNTERS
    • 6.3.3.1 Increasing research on cancer and stem cell to sustain growth
  • 6.3.4 OTHER EQUIPMENT

7 MICROCARRIERS MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 BIOPHARMACEUTICAL PRODUCTION
  • 7.2.1 VACCINE PRODUCTION
    • 7.2.1.1 Shifting patterns in vaccine development and delivery to promote growth
  • 7.2.2 THERAPEUTIC PROTEIN PRODUCTION
    • 7.2.2.1 Growing applications of recombinant proteins to fuel market
• 7.3 TISSUE ENGINEERING & REGENERATIVE MEDICINES, BY THERAPY TYPE
  • 7.3.1 CELL & GENE THERAPY
    • 7.3.1.1 Increasing development of novel microcarriers to amplify growth
  • 7.3.2 OTHER THERAPIES
• 7.4 TISSUE ENGINEERING & REGENERATIVE MEDICINES, BY CELL TYPE
  • 7.4.1 STEM CELLS
    • 7.4.1.1 Need for 3D environment for cell growth and differentiation to intensity growth
  • 7.4.2 IMMUNE CELLS
    • 7.4.2.1 Growing development of microcarrier beads to propel market
  • 7.4.3 OTHER CELL TYPES
• 7.5 OTHER APPLICATIONS

8 MICROCARRIERS MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 8.2.1 GROWING ADOPTION OF MICROCARRIERS FOR PRODUCTION OF VACCINES AND MONOCLONAL ANTIBODIES TO DRIVE MARKET
• 8.3 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS
  • 8.3.1 RISING FOCUS ON DRUG DISCOVERY, CLINICAL TRIALS, AND COMMERCIAL MANUFACTURING TO AID GROWTH
• 8.4 ACADEMIC & RESEARCH INSTITUTES
  • 8.4.1 INCREASING COLLABORATIONS BETWEEN ACADEMIC INSTITUTES AND PHARMA COMPANIES TO AUGMENT GROWTH
• 8.5 CELL BANKS
  • 8.5.1 GROWING FOCUS ON DEVELOPING ADVANCED TREATMENT METHODS TO PROPEL MARKET

9 MICROCARRIERS MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 Robust investments for life science research to contribute to growth
  • 9.2.3 CANADA
    • 9.2.3.1 Growing advancements in regenerative medicine to drive market
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Growing adoption of inorganic growth strategies by key players to boost market
  • 9.3.3 FRANCE
    • 9.3.3.1 Favorable government initiatives to intensify growth
  • 9.3.4 UK
    • 9.3.4.1 Rising focus on cancer research to expedite growth
  • 9.3.5 ITALY
    • 9.3.5.1 Increasing research on biotechnology, pharmaceuticals, and medical devices to promote growth
  • 9.3.6 SPAIN
    • 9.3.6.1 Rise in facility expansions and investments toward bioprocessing technologies to augment growth
  • 9.3.7 SWITZERLAND
    • 9.3.7.1 Favorable regulatory environment to boost growth
  • 9.3.8 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 CHINA
    • 9.4.2.1 Growing inclination toward domestic production to drive market
  • 9.4.3 JAPAN
    • 9.4.3.1 Increasing geriatric population to foster growth
  • 9.4.4 INDIA
    • 9.4.4.1 Booming biotechnology industry to spur growth
  • 9.4.5 SOUTH KOREA
    • 9.4.5.1 Growing foreign investments to drive market
  • 9.4.6 AUSTRALIA
    • 9.4.6.1 Increasing focus on biomanufacturing to assist growth
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 Expanding pharmaceutical and biopharmaceutical industries to favor growth
  • 9.5.3 MEXICO
    • 9.5.3.1 Rising investments in biotech research and production to accelerate growth
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST
  • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 Saudi Arabia
      • 9.6.2.1.1 Increasing healthcare expenditure to bolster growth
    • 9.6.2.2 UAE
      • 9.6.2.2.1 Growing focus on biopharmaceutical industry to propel market
    • 9.6.2.3 Rest of GCC Countries
  • 9.6.3 REST OF MIDDLE EAST
• 9.7 AFRICA
  • 9.7.1 NEED FOR EFFECTIVE DIAGNOSIS OF INFECTIOUS DISEASES TO SUSTAIN GROWTH
  • 9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023
• 10.3 REVENUE ANALYSIS, 2021-2023
• 10.4 MARKET SHARE ANALYSIS, 2023
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Product footprint
    • 10.5.5.4 Application footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 10.6.5.1 Detailed list of key startups/SMEs
    • 10.6.5.2 Competitive benchmarking of key startups/SMEs
• 10.7 COMPANY VALUATION AND FINANCIAL METRICS
• 10.8 BRAND/PRODUCT COMPARISON
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS

11 COMPANY PROFILES

• 11.1 MAJOR PLAYERS
  • 11.1.1 THERMO FISHER SCIENTIFIC INC.
    • 11.1.1.1 Products offered
    • 11.1.1.2 Recent developments
      • 11.1.1.2.1 Product launches
      • 11.1.1.2.2 Deals
      • 11.1.1.2.3 Expansions
    • 11.1.1.3 MnM view
      • 11.1.1.3.1 Key strengths
      • 11.1.1.3.2 Strategic choices
      • 11.1.1.3.3 Weaknesses and competitive threats
  • 11.1.2 SARTORIUS AG
    • 11.1.2.1 Products offered
    • 11.1.2.2 Recent developments
      • 11.1.2.2.1 Deals
      • 11.1.2.2.2 Expansions
    • 11.1.2.3 MnM view
      • 11.1.2.3.1 Key strengths
      • 11.1.2.3.2 Strategic choices
      • 11.1.2.3.3 Weaknesses and competitive threats
  • 11.1.3 DANAHER CORPORATION
    • 11.1.3.1 Products offered
    • 11.1.3.2 Recent developments
      • 11.1.3.2.1 Product launches
      • 11.1.3.2.2 Deals
      • 11.1.3.2.3 Expansions
    • 11.1.3.3 MnM view
      • 11.1.3.3.1 Key strengths
      • 11.1.3.3.2 Strategic choices
      • 11.1.3.3.3 Weaknesses and competitive threats
  • 11.1.4 MERCK KGAA
    • 11.1.4.1 Products offered
    • 11.1.4.2 Recent developments
      • 11.1.4.2.1 Product launches
      • 11.1.4.2.2 Deals
      • 11.1.4.2.3 Expansions
  • 11.1.5 CORNING INCORPORATED
    • 11.1.5.1 Products offered
    • 11.1.5.2 Recent developments
      • 11.1.5.2.1 Deals
  • 11.1.6 FUJIFILM HOLDINGS CORPORATION
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product launches
      • 11.1.6.3.2 Expansions
  • 11.1.7 BECTON, DICKINON & CO
    • 11.1.7.1 Products offered
    • 11.1.7.2 Recent developments
      • 11.1.7.2.1 Product launches
  • 11.1.8 EPPENDORF SE
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Product launches
      • 11.1.8.3.2 Expansions
  • 11.1.9 LONZA
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Product launches
      • 11.1.9.3.2 Deals
  • 11.1.10 GETINGE AB
    • 11.1.10.1 Products offered
    • 11.1.10.2 Recent developments
      • 11.1.10.2.1 Product launches
      • 11.1.10.2.2 Deals
  • 11.1.11 ENTEGRIS
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
  • 11.1.12 BIO-RAD LABORATORIES, INC.
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
  • 11.1.13 KURARAY CO., LTD.
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Product launches
      • 11.1.13.3.2 Expansions
  • 11.1.14 TEIJIN LIMITED
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
    • 11.1.14.3 Recent developments
      • 11.1.14.3.1 Product launches
  • 11.1.15 ASAHI KASEI CORPORATION
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products offered
• 11.2 OTHER PLAYERS
  • 11.2.1 CELLEVATE AB
  • 11.2.2 PBS BIOTECH, INC.
  • 11.2.3 SOLIDA BIOTECH GMBH
  • 11.2.4 REPROCELL INC.
  • 11.2.5 G&G TECHNOLOGIES, INC.
  • 11.2.6 DENOVOMATRIX GMBH
  • 11.2.7 BIO-LINK
  • 11.2.8 BBI-BIOTECH GMBH
  • 11.2.9 SMART MCS PTY LTD
  • 11.2.10 BIONET

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS